

REMARKS

I. Formal Matters

Claims 1-6 are pending in this application. The Examiner has rejected claims 3 and 5 for enablement and objected to claims 4 and 6 for depending on rejected base claims. Applicants have amended claims 3 and 5 and canceled claims 4 and 6.

New claims 3 and 5 find support in Example 16 on page 27, beginning on line 15 of the specification, especially lines 17 and 18 of page 27. Accordingly, no new matter has been added.

II. Enablement Rejection Under 35 U.S.C. § 112

The Examiner has rejected claims 3 and 5 under 35 U.S.C. § 112, first paragraph because the specification is allegedly not enabled because it does not give any guidance as to the full range of cancer diseases that could be treated using the claimed compound. See Office Action, Jan. 25, 2008, at 3. The Examiner suggested that the claims be limited to the diseases previously recited in claim 4. *Id.*, at 4.

Without acquiescing to this rejection, Applicants have amended claims 3 and 5 to recite the suggested particular types of cancer in an effort to facilitate prosecution. Consequently, Applicants request that the Examiner withdraw this rejection.

In view of the foregoing amendments and remarks, Applicants respectfully request reconsideration and reexamination of this application and the timely allowance of the pending claims.

PATENT
Customer No. 22,852
Attorney Docket No. **05823.0274-00000**

Please grant any extensions of time required to enter this response and charge
any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 23, 2008

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796